Cas:19466-47-8 Stigmastanol manufacturer & supplier

Chemical Name:Stigmastanol

CAS.NO:19466-47-8

Synonyms:β-Sitostanol;3-O-acetylfucosterol;Stigmastan-3β-ol;Fucosterol acetate;(3b)-Stigmastan-3-ol;Dihydro-β-sitosterol;24-METHYLENE CHOL ESTEROL ACETATE;Stigmastan-3-ol, (3β)-;fucosteryl acetate;Stigmastanol;(3β)-Stigmastan-3-ol;isofucosteryl acetate;MFCD00021167

Molecular Formula:C₂₉H₅₂O

Molecular Weight:416.723

HS Code:

Physical and Chemical Properties:

Melting point:137ºC

Boiling point:471.9±13.0 °C at 760 mmHg

Density:0.9±0.1 g/cm3

Index of Refraction:1.501

PSA:20.23000

Exact Mass:416.401825

LogP:11.10

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like β-Sitostanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00021167 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,24-METHYLENE CHOL ESTEROL ACETATE Use and application,(3β)-Stigmastan-3-ol technical grade,usp/ep/jp grade.

Related News: Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%. Stigmastanol manufacturer Slower growth in pesticide intermediates weighed on industrial business. In the first three quarters, the company’s operating income was 2.977 billion yuan, a year-on-year increase of 2.57%. Stigmastanol supplier On April 8, a group of employees filed an anonymous complaint internally alleging that an executive at its Branchburg, New Jersey, factory had altered documents required by the U.S. Food and Drug Administration. Stigmastanol vendor In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. Stigmastanol factory Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend.